4月30日 - ** 券商Leerink Partners将诊断公司Quanterix QTRX.O的评级从 "跑赢大盘 "下调至 "市场表现"，理由是与Akoya AKYA.O的交易已经修正，"仍然分散了核心业务的注意力"，并给市场带来了挑战。
** 券商还将该股的目标价从12美元下调至8美元，较上一交易日收盘价上涨32.2%。
** 券商怀疑 QTRX 能否在处理自身供应链和关税问题的同时成功整合 AKYA
** AKYA的空间蛋白质组学业务正处于市场 "疲软期"，2024年收入将下降15%，这将给QTRX带来额外的挑战--Leerink。
** 补充说，QTRX 面临的另一个挑战是 "关税风险不大"，但仍要求他们在贸易不确定性中重新评估和调整供应链
** 称 QTRX 面临 "核心学术市场的压力 "和 "制药业资金回流"。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.